Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study

#999

Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.

Aim(s): To evaluate in a prospective study P-CT changes in pNET liver metastasis (LM) during E.

Materials and methods: We evaluated eight LM from three patients with G1-2 pNETs. P-CT was performed at baseline (T0), after two (T1) and four (T2) months of E on a 64-row multidetector CT scan. A single ROI was drawn within each LM on the main axial slice. Perfusion (PF), Time to Peak (TTP), Peak Enhancement Intensity (PEI) and Blood Volume (BV) were calculated.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cingarlini S

Authors: Ortolani S, De Robertis R, Cingarlini S, D'Onofrio M, Crosara S,

Keywords: everolimus, pNET, P-CT,